促红细胞生成素的心血管效应：最新进展
Cardiovascular effects of erythropoietin an update.
作者信息
Santhanam Anantha Vijay R, d'Uscio Livius V, Katusic Zvonimir S
机构信息
Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
出版信息
Adv Pharmacol. 2010;60:257-85. doi: 10.1016/B978-0-12-385061-4.00009-X.
Erythropoietin (EPO) is a therapeutic product of recombinant DNA technology and it has been in clinical use as stimulator of erythropoiesis over the last two decades. Identification of EPO and its receptor (EPOR) in the cardiovascular system expanded understanding of physiological and pathophysiological role of EPO. In experimental models of cardiovascular and cerebrovascular disorders, EPO exerts protection either by preventing apoptosis of cardiac myocytes, smooth muscle cells, and endothelial cells, or by increasing endothelial production of nitric oxide. In addition, EPO stimulates mobilization of progenitor cells from bone marrow thereby accelerating repair of injured endothelium and neovascularization. A novel signal transduction pathway involving EPOR--β-common heteroreceptor is postulated to enhance EPO-mediated tissue protection. A better understanding of the role of β-common receptor signaling as well as development of novel analogs of EPO with enhanced nonhematopoietic protective effects may expand clinical application of EPO in prevention and treatment of cardiovascular and cerebrovascular disorders.
促红细胞生成素（EPO）是一种重组DNA技术的治疗产品，在过去二十年中一直作为红细胞生成的刺激剂用于临床。在心血管系统中对EPO及其受体（EPOR）的鉴定扩展了对EPO生理和病理生理作用的认识。在心血管和脑血管疾病的实验模型中，EPO通过防止心肌细胞、平滑肌细胞和内皮细胞凋亡，或通过增加内皮细胞一氧化氮的产生来发挥保护作用。此外，EPO刺激祖细胞从骨髓中动员出来，从而加速受损内皮的修复和新血管形成。推测一种涉及EPOR-β共同异源受体的新型信号转导途径可增强EPO介导的组织保护作用。更好地理解β共同受体信号传导的作用以及开发具有增强非造血保护作用的新型EPO类似物可能会扩大EPO在预防和治疗心血管和脑血管疾病中的临床应用。
Zotero 插件